In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Brian Fisher
- Phone Number: 415-651-3344
- Email: info@cloudcath.com
Study Locations
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico
- CloudCath Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Males or females with end-stage renal disease on peritoneal dialysis for a minimum of 10 days prior to obtaining the specimen.
- Specimens shall be leftover (or remnant) from a specimen that has been drained as part of the routine care for the patient.
- Specimens shall not contain any individually identifiable information from the patient it was obtained from.
Exclusion Criteria:
- Patients providing specimens should not be under the administration of any antibiotics other than those utilized for the treatment of peritonitis.
- Patients providing specimens should not suffer from a known liver disease or from ovarian or liver cancer.
- Patients providing specimens should not be under the administration of calcium channel blockers or amlodipine for less than 30 days prior to providing a specimen.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Peritoneal dialysis patients
Patients undergoing peritoneal dialysis.
Patients may be using either Continuous Ambulatory Peritoneal Dialysis (CAPD), Continuous Cycling Peritoneal Dialysis (CCPD) or Intermittent Peritoneal Dialysis (IPD).
|
Effluent dialysate samples evaluated for evidence of peritonitis
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Spectral measurements of effluent dialysate solutions
Time Frame: immediately post dialysis
|
a quantitative analysis of the spectral characteristics of the effluent dialysate solution using a proprietary algorithm and sensing equipment that results in a quantitative CloudCath Score.
|
immediately post dialysis
|
|
Conductivity measurements of effluent dialysate solutions.
Time Frame: immediately post dialysis
|
a quantitative assessment of conductivity of the effluent dialysate solution using a proprietary algorithm and sensing equipment that results in a quantitative CloudCath Score.
|
immediately post dialysis
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Ben Briggs, MD, PhD, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Infections
- Kidney Diseases
- Urologic Diseases
- Peritoneal Diseases
- Disease Attributes
- Renal Insufficiency
- Renal Insufficiency, Chronic
- Intraabdominal Infections
- Chronic Disease
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Kidney Failure, Chronic
- Peritonitis
- Pharmaceutical Solutions
- Dialysis Solutions
Other Study ID Numbers
Other Study ID Numbers
- CC-L-003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.